Citius Pharmaceuticals (CTXR) EBT (2010 - 2026)
Citius Pharmaceuticals' (CTXR) quarterly EBT came in at -$28.3 million in Q1 2026, down 151.98% YoY from $54.5 million in Q1 2025, and down 210.43% on a QoQ basis from -$9.1 million in Q4 2025.
Citius Pharmaceuticals (CTXR) EBT (2010 - 2026) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 17 years of EBT data on file, last reported at -$28.3 million in Q1 2026.
- Quarterly EBT fell 151.98% year-over-year to -$28.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$54.9 million (down 28.77% YoY) and the FY2025 annual result came in at -$38.7 million, changed 0.43% from the prior year.
- EBT declined to -$28.3 million in Q1 2026, from -$9.1 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$3.4 million in Q4 2022 to a low of -$28.3 million in Q1 2026.
- A 5-year average of -$10.0 million and a median of -$9.1 million in 2023 frame the typical range for EBT.
- Annual changes were most pronounced in 2022 — EBT soared 62.61% — and 2023, when it sank 163.42%.
- Tracing CTXR's EBT over 5 years: stood at -$3.4 million in 2022, then slumped by 163.42% to -$9.1 million in 2023, then retreated by 10.23% to -$10.0 million in 2024, then grew by 8.86% to -$9.1 million in 2025, then plunged by 210.43% to -$28.3 million in 2026.
- The last three EBT figures came in at -$28.3 million (Q1 2026), -$9.1 million (Q4 2025), and -$8.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Citius Pharmaceuticals | 15.60 Mn | 15.60 Mn | 1.00 Mn | -12.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.34 Mn |
| Dec 31, 2025 | -9.13 Mn |
| Sep 30, 2025 | -8.48 Mn |
| Jun 30, 2025 | -8.94 Mn |
| Mar 31, 2025 | -11.25 Mn |
| Dec 31, 2024 | -10.02 Mn |
| Sep 30, 2024 | -10.93 Mn |
| Jun 30, 2024 | -10.43 Mn |
| Mar 31, 2024 | -8.40 Mn |
| Dec 31, 2023 | -9.09 Mn |
| Sep 30, 2023 | -9.80 Mn |
| Jun 30, 2023 | -8.34 Mn |
| Mar 31, 2023 | -10.38 Mn |
| Dec 31, 2022 | -3.45 Mn |
| Sep 30, 2022 | -7.41 Mn |
| Jun 30, 2022 | -8.86 Mn |
| Mar 31, 2022 | -7.56 Mn |
| Dec 31, 2021 | -9.23 Mn |
| Sep 30, 2021 | -5.13 Mn |
| Jun 30, 2021 | -15.01 Mn |